Advertisement

Buy track record

How this insider's open-market purchases have performed
31%
of buys now in profit
4 up · 9 down
Avg return since buy−22.1%
Median return−29.5%
Best trade+38.0%
Worst trade−65.2%
Buys scored13
Average return by holding period — separates good entry timing from riding one long winner
After 1 month −2.4% 54% won · 13 trades
After 3 months −9.6% 42% won · 12 trades
After 6 months −1.7% 25% won · 8 trades
After 12 months −37.0% 0% won · 6 trades
DateCompany90d trendBuy priceValueΔOwn1M3M6M12MTo date
May 8, 2026 AVTR $8 $83.2K +20% +16.6% +13.0%
Mar 9, 2026 XRAY $12 $186.7K +30% −7.3% −18.2% −21.2%
Mar 3, 2026 XRAY $14 $314.9K +81% −12.5% −27.5% −24.1%
Mar 2, 2026 XRAY $14 $392.5K NEW −18.7% −31.3% −29.5%
Feb 19, 2026 AVTR $9 $458K NEW −17.4% −17.0% +2.0%
Dec 8, 2025 MRVI $4 $178.1K +46% +6.6% +0.6% +39.6% +38.0%
Dec 5, 2025 MRVI $4 $190.4K +93% +2.4% −0.5% +35.7% +34.6%
Mar 3, 2025 XRAY $17 $250K +23% −13.9% +0.4% −11.2% −12.8% −33.8%
Nov 18, 2024 XRAY $18 $91.8K +7.5% +1.2% +2.9% −8.2% −42.1% −42.2%
Nov 15, 2024 XRAY $18 $18.3K +6.7% +7.2% +3.9% −8.0% −40.7% −41.6%
Aug 8, 2024 XRAY $24 $200K +14% +4.2% −26.2% −23.1% −44.9% −55.9%
May 31, 2024 XRAY $28 $100K +6.5% −11.5% −10.2% −28.4% −42.5% −61.4%
Nov 22, 2023 XRAY $31 $314.4K +30% +12.3% +7.5% −9.8% −38.9% −65.2%
How this is calculated. We score only open-market purchases (SEC code P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 13 scored trades, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$2.78M
13 trades
Open-market sells
$915.7K
1 trades
Net flow
+$1.86M
Net buying
Total filings
44
transactions shown

Full transaction history

All Form 4 activity across every company, newest first
View on SEC EDGAR ↗
XRAY
Buy LUCIER GREGORY T · Director · Open-market purchase · filed Jun 3, 2024 ΔOwn +6.5%

Lucier Gregory T, XRAY's Director, spent $100K of their own money on 3,577 shares at $28, growing their stake 7%.

+$100K
3,577 sh @ $28
Advertisement
XRAY
Buy LUCIER GREGORY T · Director · Open-market purchase · filed Nov 27, 2023 ΔOwn +30%

Lucier Gregory T, XRAY's Director, spent $314.4K of their own money on 10,000 shares at $31, growing their stake 30%.

+$314.4K
10,000 sh @ $31

Frequently asked questions

How is LUCIER GREGORY T's win rate calculated?

We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.

Why are some buys not included in the score?

A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.

What do the 1M / 3M / 6M / 12M columns mean?

They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.

Does a high win rate mean I should copy this insider?

No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.

Where does this data come from?

Trades come from LUCIER GREGORY T's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.